Embed Size (px)
Citation preview
Bowel Cancer in Tasmania• In 2013, there were 439 new cases and 155 deaths from bowel cancer in Tasmania.
Encouraging your patients to screen regularly means bowel cancers can be prevented or diagnosed in its earliest stages to improve treatment outcomes. (Stokes, B, Albion, T, Otahal, P, Venn, A, Cancer in Tasmania: Incidence and Mortality 2013, Menzies Research Institute Tasmania, Hobart, December 2015)
• The five year survival rate for bowel cancer in Tasmania is only 61.6%. This is because of the late stage diagnosis. Compared to other commonly diagnosed cancers such as breast, prostate and melanoma of the skin, bowel cancer has the lowest 5-year survival rate. (Tasmanian Cancer Registry 2012, Cancer Survival and Prevalence Tasmania 1978-2008, Menzies Research Institute of Tasmania, viewed March 2017)
• 93% of patients with Stage IV bowel cancer will not survive 5 years. (Australian Bureau of Statistics (ABS) 2005, Australian Social Trends 2005, cat. no. 4102.0, ABS, Canberra, viewed March 2017)
SurvivalScreening with an iFOBT can detect precancerous lesions preventing the development of bowel cancer.
Key Facts• The NHMRC recommends that all
Australians aged 50 to 74 years should have an iFOBT every 2 years.
• By 2020, the NBCSP will be inviting all eligible 50-74 year olds every 2 years.
• You should refer all NBCSP participants with a positive iFOBT to colonoscopy as a Category One patient.
• Your patients with a positive NBCSP screening test should not be referred for another FOBT.
• There is a 30-50% probability that patients with a positive iFOBT will have a neoplastic lesion, adenoma or polyp (high Positive Predictive Value)
The National Bowel Cancer Screening Program (NBCSP) – Status
Update
Population Screening and Cancer Prevention
June 2017
Clinical GuidelinesYou can access the RACGP Clinical Guidelines for Early Detection of Colorectal Cancer on the RACGP website (http://www.racgp.org.au/your-practice/guidelines/redbook/9-early-detection-of-cancers/92-colorectal-cancer/)
Diagnosis
Image: Cancer Research UK, viewed March 2017
NBCSP Status Update
Only 44.3% of eligible Tasmanians participated in the NBCSP in 2016.
In 2016, 8.6% of Tasmanians who completed their screening test had a positive result.
More women return the screening test than men, however, more men are diagnosed with bowel cancer than women.
The age cohorts invited to screen in 2017 are: 50, 54, 55, 58, 60, 64, 68, 70, 72, and 74.
As a GP you are essential to the success of the NBCSP and we encourage you to: Recommend your
patients undertake the NBCSP test when they receive their free kit in the mail
Promptly refer participants with a positive iFOBT for colonoscopy
Ensure your patient’s NBCSP Participant ID number and Dorevitch Pathology Positive Result Letter is included in the referral.
Page 2 of 3
www.ths.tas.gov.au/cancerscreening
ContactFor further information, contact:
The Tasmanian NBCSP Participant Follow-Up Coordinators
Phone: 6166 6910Email: [email protected]
The Australian NBCSP Information Line Phone: 1800 118 868
Page 3 of 3
